Document Detail


(Mis)treating the pharmacogenetic incidentalome.
MedLine Citation:
PMID:  22293554     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to have narrower implications than suggested by initial studies.
Authors:
Isaac S Kohane
Related Documents :
1238884 - What kind of criteria?
10827294 - Integrated care: the impact of governmental behaviour on collaborative networks.
10248084 - Conversations with a gerontologist.
22833474 - A narrative literature review of the contribution of volunteers in end-of-life care ser...
15718184 - Financial aspects of heart failure programs of care.
7536224 - Perceived occurrence and importance of caring behaviours among patients and staff in ps...
Publication Detail:
Type:  Journal Article     Date:  2012-02-01
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012  
Date Detail:
Created Date:  2012-02-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  89-90     Citation Subset:  IM    
Affiliation:
Harvard Medical School Center for Biomedical Informatics, 10 Shattuck Street, Boston, Massachusetts 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The deposition of iron and silver nanoparticles in graphene-polyelectrolyte brushes.
Next Document:  Ruxolitinib.